The characteristic features of MetS, i.e., increased triglyceridemia, abdominal obesity, reduced HDL-C levels and increased glycemia, in addition to raised blood pressure, clearly indicate that PPAR-α agonists have an ideal profile to control most of these features [59]. Here, PPARA is linked to metabolic syndrome.